Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marc-Andrea Baertsch"'
Autor:
John W. Hickey, Maximillian Haist, Nina Horowitz, Chiara Caraccio, Yuqi Tan, Andrew J. Rech, Marc-Andrea Baertsch, Xavier Rovira-Clavé, Bokai Zhu, Gustavo Vazquez, Graham Barlow, Eran Agmon, Yury Goltsev, John B. Sunwoo, Markus Covert, Garry P. Nolan
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113494- (2023)
Summary: Antigen-specific T cells traffic to, are influenced by, and create unique cellular microenvironments. Here we characterize these microenvironments over time with multiplexed imaging in a melanoma model of adoptive T cell therapy and human pa
Externí odkaz:
https://doaj.org/article/23bca3d4eb344078ba8c41980512f8de
Autor:
Marc-Andrea Baertsch, Sarah Decker, Leona Probst, Stefan Joneleit, Hans Salwender, Franziska Frommann, Hartwig Buettner
Publikováno v:
JMIR Cancer, Vol 8, Iss 2, p e35500 (2022)
BackgroundPatients with multiple myeloma (MM) have high information needs due to the complexity of the disease and variety of treatments. Digital voice assistants provide support in daily life and can be a convenient tool that even older patients can
Externí odkaz:
https://doaj.org/article/5cdf727d76cf4f20b1c3766a80120ce9
Autor:
Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking Myeloma Multicenter Group (GMMG)
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared borte
Externí odkaz:
https://doaj.org/article/c1262202ec704fb3bc2b8009125681e4
Autor:
Mathias Felix Leber, Marc-Andrea Baertsch, Sophie Caroline Anker, Luisa Henkel, Hans Martin Singh, Sascha Bossow, Christine E. Engeland, Russell Barkley, Birgit Hoyler, Jessica Albert, Christoph Springfeld, Dirk Jäger, Christof von Kalle, Guy Ungerechts
Publikováno v:
Molecular Therapy: Oncolytics, Vol 9, Iss , Pp 30-40 (2018)
Measles viruses derived from the live-attenuated Edmonton-B vaccine lineage are currently investigated as novel anti-cancer therapeutics. In this context, tumor specificity and oncolytic potency are key determinants of the therapeutic index. Here, we
Externí odkaz:
https://doaj.org/article/3ac6d46b434544aa83816903d7d36f0e
Autor:
Marc-Andrea Baertsch, Sarah Decker, Leona Probst, Stefan Joneleit, Hans Salwender, Franziska Frommann, Hartwig Buettner
BACKGROUND Patients with multiple myeloma (MM) have high information needs due to the complexity of the disease and variety of treatments. Digital voice assistants provide support in daily life and can be a convenient tool that even older patients ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10e730de4aa16f0661ca697005aabfef
https://doi.org/10.2196/preprints.35500
https://doi.org/10.2196/preprints.35500
Autor:
Hartmut Goldschmidt, Marc-Steffen Raab, Carsten Müller-Tidow, Sandra Sauer, Jens Hillengass, Karin Jordan, Mathilde Fougereau, I. Breitkreutz, Thomas Hielscher, Marc-Andrea Baertsch, Nicola Giesen
Publikováno v:
Cancers, Vol 13, Iss 4706, p 4706 (2021)
Cancers
Volume 13
Issue 18
Cancers
Volume 13
Issue 18
Simple Summary High-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a standard treatment in patients with newly diagnosed multiple myeloma (MM). At relapse, salvage HDCT/ASCT is a treatment option in patients with sufficient
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 145:2445-2455
The 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg. Main topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current the
Autor:
Markus Munder, Hartmut Goldschmidt, Hans Salwender, Marc S. Raab, Jana Schlenzka, Martin Goerner, Marc-Andrea Baertsch, Martin Hoffmann, Peter Brossart, Dirk Hose, Anna Jauch, Jan Dürig, Stephan Fuhrmann, Steffen Luntz, Christina Kunz, Jens Hillengaß, Hans-Walter Lindemann, Kai Neben, Elias K. Mai, Henk M. Lokhorst, Thomas Hielscher, Ulrich Dührsen, Igor Wolfgang Blau, Hans Martin, Mathias Hänel, Pieter Sonneveld, Christof Scheid, Katja Weisel, Uta Bertsch, Helga Bernhard, Anja Seckinger, Britta Besemer
Publikováno v:
Blood Cancer Journal
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BT
Autor:
Jana Schlenzka, Stefan Klein, Mathias Haenel, Sandra Sauer, Dirk Hose, Hans Martin, Hartmut Goldschmidt, Christoph Scheid, Katja Weisel, Thomas Hielscher, Peter Reimer, Christina Habermehl, Richard Noppeney, Axel Nogai, Hans Walter Lindemann, Anna Jauch, Martin Schmidt-Hieber, Jens Hillengass, Anja Seckinger, Carsten Müller-Tidow, Peter Brossart, Natalia Becker, Marc-Andrea Baertsch, Martin Goerner, Ullrich Graeven, Roland Fenk, Hans Salwender, Steffen Luntz, Britta Besemer, Marc-Steffen Raab
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4399c16d37e08b020bece56144f3c788
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85088250853
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85088250853
Autor:
Christoph Springfeld, Sophie Caroline Anker, Sascha Bossow, Mathias F. Leber, Christof von Kalle, Russell Barkley, Jessica Albert, Guy Ungerechts, Birgit Hoyler, Dirk Jäger, Christine E. Engeland, Hans Martin Singh, Marc Andrea Baertsch, Luisa Henkel
Publikováno v:
Molecular Therapy: Oncolytics, Vol 9, Iss, Pp 30-40 (2018)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Measles viruses derived from the live-attenuated Edmonton-B vaccine lineage are currently investigated as novel anti-cancer therapeutics. In this context, tumor specificity and oncolytic potency are key determinants of the therapeutic index. Here, we